Cerevance Announces Poster Presentation at the BNA International Festival of Neuroscience
13 Apr 2023
Phase 2Clinical Result
BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Cerevance a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced a poster presentation at the British Neuroscience Association (BNA) 2023 International Festival of Neuroscience in Brighton, United Kingdom being held April 23-26, 2023.
Title: NETSseq platform identifies KCNK13 (THIK-1) as a target to modulate neuroinflammation in Alzheimer’s disease
Overview: The NETSseq platform can identify novel druggable microglia targets, exemplified by KCNK13, as potential therapies for neurodegenerative diseases. The discovery of a KCNK13 inhibitor, C101248, is described.
Presenter: Sam Russell
Session Date and Time: April 23, 2023; 2:40-4:20pm
About Cerevance
Cerevance is a private pharmaceutical company with a focus on CNS disorders. CVN424, Cerevance’s lead therapeutic, is a first-in-class, oral, non-dopaminergic compound acting on a novel target (GPR6), that demonstrated significant and clinically meaningful efficacy in a 136-patient Phase 2 study in patients with Parkinson’s disease. The company uses its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to identify highly selectively expressed, novel target proteins that are either specific to certain brain circuits or are over- or under-expressed in diseased brains. Partnering with over 25 brain banks and evaluating an expanding collection of more than 12,000 human post-mortem brain tissue samples, Cerevance is advancing a robust pipeline of targeted treatments for patients with neurodegenerative diseases, including Parkinson’s disease, Amyotrophic Lateral Sclerosis and Alzheimer’s disease. For additional information, please visit
Contacts
Cerevance:
Johnna Simoes, ir@cerevance.com
Media:
Andrew Mielach, amielach@lifescicomms.com, +1-646-876-5868
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.